Accessibility Menu
Cidara Therapeutics Stock Quote

Cidara Therapeutics (NASDAQ: CDTX)

$93.11
(-3.2%)
-3.05
Price as of October 24, 2025, 3:58 p.m. ET

KEY DATA POINTS

Current Price
$93.12
Daily Change
(-3.2%) $3.05
Day's Range
$93.00 - $97.74
Previous Close
$93.12
Open
$97.74
Beta
0.71
Volume
652,166
Average Volume
763,410
Market Cap
2.4B
Market Cap / Employee
$93.12M
52wk Range
$12.10 - $121.21
Revenue
-
Gross Margin
0.25%
Dividend Yield
N/A
EPS
-$11.14
CAPs Rating
-
Industry
Biotechnology

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Cidara Therapeutics Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
CDTX+734.41%+53.66%+8.96%-71%
S&P+16.9%+95.99%+14.39%+222%

Cidara Therapeutics Company Info

Cidara Therapeutics, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of therapeutics for patients facing serious diseases, specifically oncology and infectious diseases. Its product pipeline includes Rezafungin Acetate and Cloudbreak. The company was founded by Kevin M. Forrest, Kevin J. Judice, and H. Shaw Warren in December 2012 and is headquartered in San Diego, CA.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$0.00M-100.0%
Gross Profit-$0.03M-111.0%
Gross Margin81.13%0.0%
Market Cap$631.76M1059.9%
Market Cap / Employee$16.63M0.0%
Employees38-44.9%
Net Income-$25.72M72.7%
EBITDA-$31.29M-183.3%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$516.91M214.5%
Accounts Receivable$1.86M-20.9%
Inventory00.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$0.84M-69.9%
Short Term Debt$1.50M-1.6%

Ratios

Q2 2025YOY Change
Return On Assets-33.09%65.0%
Return On Invested Capital-42.67%9.9%

Cash Flow

Q2 2025YOY Change
Free Cash Flow-$40.96M60.5%
Operating Free Cash Flow-$40.96M60.5%

Valuation

MetricQ3 2024Q4 2024Q1 2025Q2 2025YoY Change
Price to Book0.381.641.444.20-237.02%
Price to Sales1.392.6629.831011.2256068.96%
Price to Tangible Book Value0.381.641.444.20-237.02%
Enterprise Value to EBITDA3.07-1.27-4.35-7.76-181.14%
Return on Equity-203.3%-222.4%-299.6%-37.1%-77.09%
Total Debt$3.94M$3.58M$2.67M$2.33M-45.74%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.